Evaluation of dyslipidaemia and the impact of hypolipidemic therapy on prognosis in high and very high risk patients through the Hyperlipidaemia Therapy in tERtiary Cardiological cEnTer (TERCET) Registry

Dyrbuś, Krzysztof; Osadnik, Tadeusz; Desperak, Piotr; Desperak, Aneta; Gąsior, Mariusz; Banach, Maciej

doi:10.1016/j.phrs.2017.12.015

Cited by 23 publications

(15 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Statin use was associated with a 40% lower risk of mortality (RR 0.60, 0.49–0.74, p < 0.001). Finally, cumulative meta-analysis by Liu et al showed an obvious trend of reduction in mortality with statins [57, 58]. The results of our analysis in patients with HF and LVEF ≥40% are consistent with the results of Fukuta et al and Liu et al [56, 57].…”

Section: Discussionsupporting

confidence: 91%

Association of statin use and clinical outcomes in heart failure patients: a systematic review and meta-analysis

et al. 2019

Self Cite

View full text Add to dashboard Cite

BackgroundThe role of statins in patients with heart failure (HF) of different levels of left ventricular ejection fraction (LVEF) remains unclear especially in the light of the absence of prospective data from randomized controlled trials (RCTs) in non-ischemic HF, and taking into account potential statins’ prosarcopenic effects. We assessed the association of statin use with clinical outcomes in patients with HF.MethodsWe searched PubMed, EMBASE, Scopus, Google Scholar and Cochrane Central until August 2018 for RCTs and prospective cohorts comparing clinical outcomes with statin vs non-statin use in patients with HF at different LVEF levels. We followed the guidelines of the 2009 PRISMA statement for reporting and applied independent extraction by multiple observers. Meta-analyses of hazard ratios (HRs) of effects of statins on clinical outcomes used generic inverse variance method and random model effects. Clinical outcomes were all-cause mortality, cardiovascular (CV) mortality and CV hospitalization.ResultsFinally we included 17 studies (n = 88,100; 2 RCTs and 15 cohorts) comparing statin vs non-statin users (mean follow-up 36 months). Compared with non-statin use, statin use was associated with lower risk of all-cause mortality (HR 0.77, 95% confidence interval [CI], 0.72–0.83, P < 0.0001, I2 = 63%), CV mortality (HR 0.82, 95% CI: 0.76–0.88, P < 0.0001, I2 = 63%), and CV hospitalization (HR 0.78, 95% CI: 0.69–0.89, P = 0.0003, I2 = 36%). All-cause mortality was reduced on statin therapy in HF with both EF < 40% and ≥ 40% (HR: 0.77, 95% Cl: 0.68–0.86, P < 0.00001, and HR 0.75, 95% CI: 0.69–0.82, P < 0.00001, respectively). Similarly, CV mortality (HR 0.86, 95% CI: 0.79–0.93, P = 0.0003, and HR 0.83, 95% CI: 0.77–0.90, P < 0.00001, respectively), and CV hospitalizations (HR 0.80 95% CI: 0.64–0.99, P = 0.04 and HR 0.76 95% CI: 0.61–0.93, P = 0.009, respectively) were reduced in these EF subgroups. Significant effects on all clinical outcomes were also found in cohort studies’ analyses; the effect was also larger and significant for lipophilic than hydrophilic statins.ConclusionsIn conclusion, statins may have a beneficial effect on CV outcomes irrespective of HF etiology and LVEF level. Lipophilic statins seem to be much more favorable for patients with heart failure.

show abstract

Section: Discussionsupporting

confidence: 91%

Association of statin use and clinical outcomes in heart failure patients: a systematic review and meta-analysis

et al. 2019

Self Cite

View full text Add to dashboard Cite

show abstract

“…This study displayed whether CPE55 possessed hypolipidemic activity and how to affect liver gene expressions and gut microbiota. Consumption of HFD obviously increased serum TG, TC, and LDL-C levels and decreased HDL-C level, which were consistent with previously reported studies [31]. CPE55 supplementation has increased serum HDL-C level and TBA, while decreased TG, TC, and LDL-C levels during eight-weeks.…”

Section: Discussionsupporting

confidence: 92%

Effect of Marine Microalga Chlorella pyrenoidosa Ethanol Extract on Lipid Metabolism and Gut Microbiota Composition in High-Fat Diet-Fed Rats

Wan

Liú

et al. 2018

Marine Drugs

View full text Add to dashboard Cite

Effects of marine microalga Chlorella pyrenoidosa 55% ethanol extract (CPE55) on lipid metabolism, gut microbiota and regulation mechanism in high fat diet-fed induced hyperlipidaemia rats were investigated. Structure characterizations of major compounds in CPE55 were determined by ultra-performance liquid chromatography-quadrupole/time of flight mass spectrometry (UPLC-Q-TOF-MS/MS). The compositions of gut microbiota in rats were analyzed by high-throughput next-generation 16S rRNA gene sequencing. Oral administration with CPE55 markedly alleviated dyslipidemia through improving adverse blood lipid profile and inhibiting hepatic lipid accumulation and steatosis. CPE55 has downregulated the gene expression levels of acetyl CoA carboxylase, sterol regulatory element-binding transcription factor-1c, and 3-hydroxy-3-methyl glutaryl coenzyme A reductase and upregulated adenosine 5′-monophosphate-activated protein kinase-α. It has also improved the abundance of bacteria Alistipes, Prevotella, Alloprevotella, and Ruminococcus1 and decreased the abundances of Turicibacter and Lachnospira. Turicibacter and Lachnospira were both positive correlations of metabolic phenotypes. The findings above illustrated that CPE55 might be developed as food ingredients to ameliorate lipid metabolic disorders and hyperlipidaemia.

show abstract

“…However, not all patients who are overweight or obese experience such complications. For these reasons, one of the important primary prevention tools for obesity-related illnesses would be the ability to identify patients at high risk of developing obesity-related diseases as opposed to people referred to as "metabolically healthy obese" [7,8].…”

Section: Discussionmentioning

confidence: 99%

Novel inflammatory biomarkers may reflect subclinical inflammation in young healthy adults with obesity

Osadnik

Bujak

Osadnik

et al. 2019

Endokrynologia Polska

Self Cite

View full text Add to dashboard Cite

Introduction: Obesity is often accompanied by low-grade inflammation. In recent years a few blood-based inflammatory markers-neutrophil-to-lymphocyte ratio (NLR), derived neutrophil-to-lymphocyte ratio (dNLR), platelet-to-lymphocyte ratio (PLR), lymphocyteto-monocyte ratio (LMR), and monocyte-to-high-density lipoprotein ratio (MHR)-have been identified. They have been proven to correlate well with established inflammatory markers such as hsCRP and have a prognostic value among others in patients with coronary artery disease, heart failure, and malignancies. The aim of the study was to find markers associated with obesity in young heathy adults. Material and methods: The study group included 321 young healthy adults aged 18-35 years (210 males and 111 females). Partial least squares regression analysis was used to find variables associated with body mass index (BMI). Analysed variables included complete blood count, lipid profile, sex hormone levels, acute-phase protein levels, and blood-based inflammatory markers. Results: Variables with the strongest association with BMI in the group of men were HDL% and apolipoprotein B, and in the group of women, HDL, HDL%, triglycerides, and MHR. Novel inflammatory markers were not associated with BMI, except MHR. We found significant (p < 0.001) correlations between novel biomarkers (NLR, dNLR) and hsCRP and fibrinogen levels in the group of subjects with obesity. Conclusions: Blood-based inflammatory markers significantly correlate with hsCRP and fibrinogen in young healthy adults with obesity, which may reflect the subclinical inflammation in this group of individuals.

show abstract

Evaluation of dyslipidaemia and the impact of hypolipidemic therapy on prognosis in high and very high risk patients through the Hyperlipidaemia Therapy in tERtiary Cardiological cEnTer (TERCET) Registry

Cited by 23 publications

References 31 publications

Association of statin use and clinical outcomes in heart failure patients: a systematic review and meta-analysis

Association of statin use and clinical outcomes in heart failure patients: a systematic review and meta-analysis

Effect of Marine Microalga Chlorella pyrenoidosa Ethanol Extract on Lipid Metabolism and Gut Microbiota Composition in High-Fat Diet-Fed Rats

Novel inflammatory biomarkers may reflect subclinical inflammation in young healthy adults with obesity

Contact Info

Product

Resources

About